Canada markets close in 1 hour 38 minutes

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.01-0.66 (-2.30%)
As of 02:22PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close28.67
Bid28.21 x 800
Ask28.35 x 900
Day's Range26.76 - 28.95
52 Week Range26.76 - 61.69
Avg. Volume692,019
Market Cap1.169B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector CA marijuana operator Harborside to acquire Urbn Leaf, Loudpack. Marijuana industry lender Chicago Atlantic plans to become REIT with IPO. Schwazze borrows $95 million, acquires New Mexico cannabis operations. Cannabis retailer Fire & Flower consolidating shares for Nasdaq listing. Key Takeaways; Psychedelic Sector Awakn Life Sciences Strengthens Executive Leadership Team. MindMed […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared firs

  • Motley Fool

    Were Compass Pathways' Clinical Trial Results Really That Bad?

    Compass Pathways (NASDAQ: CMPS) has released data for a phase 2b study of its COMP360 psilocybin treatment for depression. In this Motley Fool Live video recorded on November 15, Motley Fool contributors Keith Speights and Brian Orelli point out that the therapy helped reduce patients' depression symptoms, but the drug's effectiveness seemed to wane over time and adverse effects were seen in patients taking higher doses.

  • Motley Fool

    Better Buy: Compass Pathways vs. Jazz Pharmaceuticals

    While both Compass Pathways (NASDAQ: CMPS) and Jazz Pharmaceuticals (NASDAQ: JAZZ) are biopharma companies, their positioning couldn't be more different. Whereas Jazz has a market cap of $8.33 billion, $2.86 billion in trailing revenue, and a pipeline that's chock-full of drug programs of all sorts, Compass is worth $1.48 billion, and it only has a few projects in the works, none of which are near completion. For investors with little expertise in pharma, it can be tough to weigh the merits of innovative companies like this pair.